Abstract Neurofibromatosis type 1 (NF1) is a dominantly inherited neurocutaneous disorder caused by mutations in the NF1 gene. Common clinical manifestations associated with NF1 are neurofibromas, café-au-lait macules (CALM), axillary freckling and Lisch nodules of the iris. Other important manifestations are vasculopathy, a variety of osseous lesions, including short stature, scoliosis and pseudoarthrosis, optic gliomas and an increased risk for certain malignancies. The best characterized function of the NF1 gene is to act as a downregulator of Ras proto-oncogene signalling by accelerating the switch of active Ras-GTP into inactive Ras-GDP. The NF1 gene is considered a tumor suppressor since some malignancies may display a loss of heterozygosity or homozygotic inactivation of the gene. The present study investigated the behaviour and function of the NF1 gene during keratinocyte differentiation, wound healing and psoriasis using human epidermis and epidermal keratinocytes as a model. The NF1 protein was shown to associate with the intermediate filament network during keratinocyte differentiation both in vitro and in vivo, and it is thus suggested to play a role in the cytoskeletal re-organization or in the formation of cell adhesions. NF1 gene expression was also studied in psoriasis, in which keratinocytes are hyperproliferative and cell differentiation is altered. NF1 gene expression was downregulated in psoriatic keratinocytes both in vivo and in vitro, suggesting that the NF1 gene might have role in downregulating keratinocyte proliferation. During epidermal wound healing, NF1 gene expression was increased. However, the process of wound healing showed no apparent differences between NF1 patients and controls. Furthermore, an increased number of cells immunoreactive for active Ras-MAPK was demonstrated in vascular tissues of NF1 patients, but not in epidermal keratinocytes or dermal fibroblasts. The finding suggests that the NF1 protein functions as a Ras-GAP in some, but not all tissues.

Bakgrund: Psoriasis är en kronisk och smärtsam folksjukdom som kan leda till lidande för den drabbade. Uppskattningsvis 2 % -10 % lever med hudsjukdomen i världen. Individuellt anpassad behandling och omvårdnad kan ge förutsättningar till en god livskvalitet och självkänsla. Syfte: Syftet med denna litteraturöversikt var att belysa psoriasis påverkan på livskvaliteten samt de drabbade personernas hantering av sjukdomen. Metod: En litteraturöversikt användes där kvantitativa och kvalitativa studier redovisades. Resultat: Resultatet visade att psoriasis både påverkade den psykiska, sociala samt den fysiska hälsan. För att hantera sjukdomen visade det sig vara viktigt med tillräcklig kunskap samt att utveckla individuella hanteringsstrategier. Diskussion: Många individer med psoriasis uppfattade sig som märkta av sjukdomen vilket påverkade livet i stor utsträckning. Reflektion över utseende och andras åsikter kan leda till en psykisk belastning samt känsla av stigmatisering. Detta kan ses som en förklaring till att depression förekommer hos en stor del av personer med psoriasis. Slutsats: För att sjuksköterskan ska kunna ge en god omvårdnad samt utbilda och stödja personer med psoriasis behövs en djupare kunskap om hur det individuella stödet kring den psykiska, sociala och fysiska hälsan ska utformas. / <p>Godkännande datum: 2016-11-01</p>

Psoriasis is a chronic skin condition that can impair physical, psychological and social functioning. A sub-population of people living with psoriasis believe that psychological stress exacerbates their physical symptoms. Stress may exacerbate psoriasis via a psychoneuroimmunological pathway. The cortisol awakening response can be used to indicate whether this pathway is functional or dysfunctional. People with psoriasis have an elevated risk of emotional distress (anxiety and depression) and an impaired quality of life. Mindfulness based cognitive therapy has been effective in reducing stress, emotional distress, quality of life impairment as well as improving physical health. The aim of this thesis is to examine the efficacy and acceptability of mindfulness-based intervention for people living with psoriasis and whether the cortisol awakening response mediates the relationship between perceived stress and physical severity of psoriasis. This thesis adopted a mixed-methods design. A pilot, randomised control trial examined the effects of mindfulness based cognitive therapy upon the physical severity, perceived stress, emotional distress, quality of life and cortisol awakening response of people living with psoriasis. These variables were entered into a correlation analysis to examine whether the cortisol awakening response was associated with any of the reported study outcomes (physical severity, perceived stress, emotional distress and quality of life). Completers of the mindfulness intervention were invited to a semi-structured interview to explore the characteristics of the participants who adhered to the intervention and their experiences of participating. The mindfulness intervention significantly improved physical (z=1.96, p=0.05) and quality of life (z=2.30, p=0.02) measurements without changing perceived stress (z=0.07, p=0.94), emotional distress (z=1.60, p=0.12) or cortisol awakening responses (z=-0.33, p=0.74). The overall cortisol awakening response was not associated with physical severity (r=-0.30, p=0.07) or perceived stress (r=-0.20, p=0.25) but was significantly correlated with emotional distress (r=-0.35, p=0.04). The intervention was perceived as an acceptable adjunct treatment option. Participants reported some process barriers that inhibited their learning of mindfulness skills. A profile emerged that described a sub-population of people with psoriasis. This sub-population may be more likely to accept and adhere to mindfulness based cognitive therapy.This thesis provides preliminary support to the concept that increasing mindfulness skill can reduce the physical severity and quality of life impairment in people with psoriasis. It recommends that a fully powered trial be conducted to examine the effectiveness of mindfulness in improving physical and overall functioning for people with psoriasis. This thesis suggests clinicians screen their patients and offer a psychological intervention best suited to their needs and characteristics.

Psoriasis is a chronic, clinically heterogeneous, skin condition that affects approximately 2% of the general population. In 1985, Henseler and Christophers, classified psoriasis into early onset (EOP; age at onset ≤40 years-y) and late onset disease (LOP; age at onset >40 y). Previous research suggests that there are genetic and immunological differences between EOP and LOP. In particular, the major genetic determinant for psoriasis, the human leukocyte antigen (HLA)-Cw6 allele, occurs more frequently in EOP (55-80%) compared to LOP (15-20%) patients. Epidermal Langerhans’ cells (LC) migration is also different in these 2 subtypes of psoriasis. The primary aim of this thesis was to further explore the clinical, histological and immunohistochemical (IHC) differences between EOP and LOP. We compared clinical characteristics in a total of 497 subjects, including 340 psoriasis patients (108 recruited prospectively; 76 EOP and 32 LOP, mean age of onset 20.3±9.9 and 55.6±7y respectively, and 232 retrospectively; 202 EOP and 30 LOP, mean age of onset 20.7±9.9 and 55.2±7.2y respectively) and 157 controls (mean age 66±11.2y). Information on demographics, family history of psoriasis, clinical features, treatment and co-morbidities were recorded. Patients were also assessed for health-related quality of life and psychological distress. A total of 31 psoriasis patients, ≥ 50y of age, participated in the histological and IHC evaluation; 17 EOP and 14 LOP, mean age of onset 21.1±8.5 and 55.4±7.7y respectively. Skin biopsies were taken from involved (PP) and uninvolved (PN) skin and stained with haematoxylin and eosin (H&E) and IHC antibodies against various T-cell (CD3, CD4, and CD8) and LC (CD1α) markers. The H&E parameters (morphological and inflammatory) were graded with the use of a study specific histological score, whilst IHC positive epidermal cells were counted per microscopic field at 200X magnification. The dermal IHC infiltrate was assessed with a semi-quantitative (0-3) scale. Gender, body mass index, disease duration and severity, diagnosed hypertension and dyslipidemia were treated as covariates. The clinical data showed that LOP patients had a lower likelihood of having a positive family history of psoriasis (62% of EOP versus 35.6% of LOP patients; chi square-x2, P=0.001). In addition, patients with EOP parent(s) were 91% less likely to develop LOP than EOP (odds ratio-OR=0.093, P=0.025, 95% confidence interval-CI 0.012-0.74). Moreover, compared to LOP, EOP patients had a more severe disease (x2, P=0.021), usually requiring 3rd line treatments (x2; P=0.010). They also experienced frequent flares, following upper respiratory tract infections (x2, P=0.049). When data were segregated by age (≥50years) and after accounting for covariates, we observed that, compared to the non-psoriasis population, LOP patients were approximately 3 times more likely to develop type 2 Diabetes Mellitus (OR=2.56, P=0.05, 95% CI 1.01-6.54), whilst, EOP subjects were 98% less likely to develop autoimmune thyroiditis (OR=0.025, P=0.02, 95% CI 0.001-0.55). Psychologically, LOP patients were found to be a clinically more anxious group compared to EOP (t-test, P=0.006). Microscopically, the results from the H&E study showed an increased total inflammatory infiltrate in LOP, PP sections compared to EOP, PP ones (t-test, P=0.028). With IHC stains, we observed that in the epidermis of LOP PP, there was a significantly higher count of CD4+ cells; mean CD4+ in LOP of 15.1 ± 6.2 versus 6.7±4.6 in EOP (Analysis of variance-ANOVA, P<0.001). This subsequently led to a higher epidermal CD4+/CD8+ ratio of 1.3 in the LOP versus 0.5 for the EOP sections (ANOVA, P=0.002). In the PP dermis, CD4+ were also more abundant in the LOP tissue (x2, P=0.049). To assess whether these CD4+ cells were either T-lymphocytes or LC, we examined for differences in the CD3+ and CD1α+ cells. The mean epidermal CD3+ tended to be higher in LOP PP sections; mean epidermal CD3+ in the LOP 42.8 ± 13.3 versus 31.7 ± 17.5 in the EOP group (ANOVA, P= 0.061), while the dermal infiltrate showed a similar pattern (x2,P=0.067). Finally, there was no difference in epidermal and dermal CD1α+ and CD8+ cells in PP between EOP and LOP sections. These data indicate differences in clinical phenotype, heritability, comorbidities and immunopathomechanism between EOP and LOP. Taken together they provide further evidence that EOP and LOP may be different diseases.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22000号 / 医博第4514号 / 新制||医||1038(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 竹内 理, 教授 杉田 昌彦 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

京都大学 / 新制・課程博士 / 博士(生命科学) / 甲第23335号 / 生博第453号 / 新制||生||60(附属図書館) / 京都大学大学院生命科学研究科統合生命科学専攻 / (主査)教授 野田 岳志, 教授 杉田 昌彦, 教授 千坂 修 / 学位規則第4条第1項該当 / Doctor of Philosophy in Life Sciences / Kyoto University / DFAM

The aim of this diploma thesis is to study and design experimental improvement of the convolutional neural network for disease detection. Another goal is to extend the classifier with a new type of detection. he new type of detection is damage fingerprint by pressure. The experimentally improved convolutional network is implemented by PyTorch. The network detects which part of the fingerprint is damaged and draws this part into the fingerprint. Synthetic fingerprints are used when training the net. Real fingerprints are added to the synthetic fingerprints.

Introduktion: Psoriasis är en kronisk inflammatorisk systemsjukdom som drabbar främst hud och leder.  På grund av mycket snabbt tillväxt av hudceller ger psoriasis utslag på huden.  En av de vanligaste typerna av psoriasis är plack-psoriasis som kännetecknas av större än 0,5 cm i diameter runda fjällande hudutslag som kliar. Mekanismen som ligger bakom plack-psoriasis medieras med hjälp av T-celler och dendritiska celler som är en viktig del av immunsystemet. Stimulering av dessa immunceller leder till frisättning av följande proinflammatoriska cytokiner såsom IL-17, IFN-γ, TNF samt IL-22. Dessa cytokiner utövar sin effekt på keratinocyter genom att öka psoriatisk inflammation. Flera biologiska läkemedel utvecklas nu för behandling av plack-psoriasis. I detta arbete har fokus lagts på två av dem, sekukinumab som är en IL-17A hämmare och ustekinumab, som är en IL-12 och IL-23 hämmare. Syfte: Syftet med arbetet är att undersöka effektivitet av sekukinumab vid behandling av plack-psoriasis. Vidare undersöks även hur behandling av plack-psoriasis med sekukinumab skiljer sig från behandling med ustekinumab gällande minskning av plack-psoriasis. Metod: Detta arbete är en litteraturstudie som inkluderar fem vetenskapliga artiklar som baserades på randomiserade kontrollerade studier som sponsrades av läkemedelsföretag.  Resultat: Resultatet av de fem studier visar att behandling med hjälp av sekukinumab 300 mg och 150 mg var mer effektiv än behandling med ustekinumab 45/90 mg, enligt PASI 75, PASI 90 och PASI 100. Diskussion: Alla fem studierna var dubbel-blinda randomiserade kontrollerade studier vilket leder till säkra och tillförlitliga resultat. Däremot var samtliga studier sponsrade av läkemedelsföretag vilket kan leda till att positiv effekt beskrivs i större utsträckning för att kunna sälja sin produkt.  Slutsats: Sekukinumab 300 mg och 150 mg är signifikant mer effektiv än placebo och signifikant mer effektiv än ustekinumab 45/90 mg vid behandling av medelsvår och svår plack-psoriasis. / Introduction: Psoriasis is a chronic inflammatory systemic disease that mainly affects the skin and joints. Due to the very rapid growth of skin cells, psoriasis causes rashes on the skin. One of the most common types of psoriasis is plaque psoriasis which is characterized by larger than 0.5 cm in diameter round scaly skin rash that itches. The mechanism behind plaque psoriasis is mediated by T cells and dendritic cells, which are an important part of the immune system. Stimulation of these immune cells leads to the release of the following proinflammatory cytokines such as IL-17, IFN-γ, TNF and IL-22. These cytokines exert their effect on keratinocytes by increasing psoriatic inflammation.  Several biological drugs are now being developed for the treatment of plaque psoriasis. In this study, the focus has been on two of them, secukinumab which is an IL-17A inhibitor and ustekinumab, which is an IL-12 and IL-23 inhibitor. Purpose: The purpose of this study is to investigate the efficacy of secukinumab in the treatment of plaque psoriasis. Furthermore, it is also investigated if the treatment of plaque psoriasis with secukinumab differs from treatment with ustekinumab regarding reduction of plaque psoriasis. Method: This work is a literature study that includes five scientific articles based on randomized controlled trials sponsored by pharmaceutical companies.  Results: The results of the five studies show that treatment with secukinumab 300 mg and 150 mg was more effective than treatment with ustekinumab 45/90 mg, according to PASI 75, PASI 90 and PASI 100. Discussion: All five studies were double-blind randomized controlled trials leading to safe and reliable results. On the other hand, all studies were sponsored by pharmaceutical companies, which may lead to a positive effect being described to a greater extent in order to be able to sell their product. Conclusion: Secukinumab 300 mg and 150 mg are significantly more effective than placebo and significantly more effective than ustekinumab 45/90 mg in the treatment of moderate to severe plaque psoriasis.

[ES] Nuestra investigación se centra en comprender los mecanismos moleculares que median las acciones de los glucocorticoides (GCs) en la fisiopatología de la piel mediante el análisis funcional del receptor de GCs (GR) y el receptor de mineralocorticoides (MR), dos proteínas altamente relacionadas estructural y funcionalmente, que actúan como factores de transcripción dependientes de ligando. Nuestros datos previos demuestran que GR juega un papel central en el desarrollo de la piel; en la edad adulta, tanto GR como MR actúan como mediadores anti-inflamatorios en enfermedades cutáneas (Sevilla et al. 2013; Boix et al. 2016). No obstante, desconocíamos si los receptores ejercían funciones cooperativas o antagónicas en la epidermis. Esta tesis doctoral se ha centrado en la generación y caracterización de ratones con inactivación específica en la epidermis de GR y MR (ratones double knock-out o DKO). Al nacer, los DKO mostraron un fenotipo cutáneo con diferenciación epidérmica defectuosa y un estado inflamatorio único caracterizado por infiltrados inmunes epiteliales y alteraciones en la expresión génica, similar a las lesiones psoriáticas. Este fenotipo fue mucho más severo que el de los KO individuales (ratones GR epidermal KO o GREKO y MR epidermal KO o MREKO), pero se resolvió espontáneamente a partir del día post-natal 3. En la edad adulta, la piel DKO mostró un aumento en el grosor epidérmico, similar al de los KO individuales. Todos los ratones KO mostraron una mayor susceptibilidad a la inflamación aguda respecto a los controles (CO), que no se contrarrestó de forma efectiva por un tratamiento tópico con GCs. Además, los ratones DKO mostraron una mayor susceptibilidad a la psoriasis inducida por imiquimod respecto a los KO individuales. El aumento de la respuesta inflamatoria en los DKO era consistente con un aumento significativo de la actividad de AP-1 y NF-kappaB en queratinocitos DKO respecto a los CO o KO individuales. En conjunto, nuestros datos demuestran que GR y MR epidérmicos actúan de manera cooperativa para contrarrestar la inflamación de la piel, durante el desarrollo y la edad adulta, y que ambos son necesarios para una respuesta transcripcional óptima y una actividad terapéutica de los GCs. Los tratamientos prolongados con dosis farmacológicas de GCs producen defectos como la atrofia cutánea, similar a la que tiene lugar durante el envejecimiento cronológico, que correlaciona con un aumento de los niveles locales endógenos de GCs. Este trabajo ha abordado las consecuencias fenotípicas de la pérdida epidérmica de MR durante el envejecimiento cronológico y los mecanismos involucrados. Los ratones MREKO de 13 meses de edad fueron resistentes a la atrofia epidérmica pero mostraron un menor grosor dérmico y depósito de colágeno, en parte debido a una disminución de la actividad SMAD2/3 respecto a la piel de ratones CO. Además, el tejido adiposo subcutáneo (dWAT) se engrosó 2.5 veces en MREKO vs CO a los 13 meses, con hiperplasia e hipertrofia de adipocitos. Estos cambios se desencadenaron, al menos en parte, a través de alteraciones en la señalización mediada por GCs, y la activación de WNT/beta-catenina inducida por señales paracrinas epidérmicas que condujeron al aumento de expresión de Pparg. Estos resultados demuestran un papel crucial de MR epidérmico en la regulación del cross-talk entre compartimientos durante el envejecimiento cronológico de la piel. / [CA] La nostra investigació se centra en comprendre els mecanismes moleculars que regulen les accions dels glucocorticoides (GCs) en la fisiopatologia de la pell mitjançant l'anàlisi funcional del receptor de GCs (GR) i el receptor de mineralocorticoides (MR), dues proteïnes altament relacionades estructural i funcionalment, que actuen com a factors de transcripció dependents de lligant. Els nostres resultats previs demostren que GR juga un paper central en el desenvolupament de la pell; en l'edat adulta, tant GR com MR actuen com a mediadors antiinflamatoris en malalties cutànies (Sevilla et al. 2013; Boix et al. 2016). No obstant, desconeixíem si els receptors exercien funcions cooperatives o antagòniques en l'epidermis. Aquesta tesi doctoral s'ha centrat en la generació i caracterització de ratolins amb inactivació específica en l'epidermis de GR i MR (ratolins double knock-out o DKO). En néixer, els DKO van mostrar un fenotip cutani amb diferenciació epidèrmica defectuosa i un estat inflamatori únic caracteritzat per infiltrats immunes epitelials i alteracions en l'expressió gènica, similar a les lesions psoriàtiques. Aquest fenotip va ser molt més sever que el dels KO individuals (ratolins GR epidermal KO o GREKO i MR epidermal KO o MREKO), però es va resoldre espontàniament a partir del dia post-natal 3. En l'edat adulta, la pell DKO va mostrar un augment en el gruix epidèrmic, similar al dels KO individuals. Tots els ratolins KO van mostrar una major susceptibilitat a la inflamació aguda en comparació als controls (CO), que no va ser contrarestada de manera efectiva per un tractament tòpic amb GCs. A més, els ratolins DKO van mostrar una major susceptibilitat a la psoriasis induïda per imiquimod respecte als KO individuals. L'augment de la resposta inflamatòria en els DKO era consistent amb un augment significatiu de l'activitat d'AP-1 i NF-kappaB en queratinòcits DKO respecte als CO o KO individuals. En conjunt, les nostres dades demostren que GR i MR epidèrmics actuen de manera cooperativa per contrarestar la inflamació de la pell, durant el desenvolupament i l'edat adulta, i que tots dos són necessaris per a una resposta transcripcional òptima i una activitat terapèutica dels GCs. Els tractaments prolongats amb dosis farmacològiques de GCs produeixen defectes com l'atròfia cutània, similar a la que té lloc durant l'envelliment cronològic, que correlaciona amb un augment dels nivells locals endògens de GCs. Aquest treball ha abordat les conseqüències fenotípiques de la pèrdua epidèrmica de MR durant l'envelliment cronològic i els mecanismes involucrats. Els ratolins MREKO de 13 mesos d'edat van ser resistents a l'atròfia epidèrmica però van mostrar un menor gruix dèrmic i dipòsit de col¿lagen, en part a causa d'una disminució de l'activitat SMAD2/3 respecte a la pell de ratolins CO. A més, el teixit adipós subcutani (dWAT) es va engrossir 2.5 vegades en MREKO vs CO als 13 mesos, amb hiperplàsia i hipertròfia d'adipòcits. Aquests canvis es van desencadenar, almenys en part, a través d'alteracions en la senyalització mediada per GCs, i l'activació de WNT/beta-catenina induïda per senyals paracrines epidèrmiques que van conduir a l'augment d'expressió de Pparg. Aquests resultats demostren un paper crucial de MR epidèrmic en la regulació del cross-talk entre compartiments durant l'envelliment cronològic de la pell. / [EN] Our research focuses on understanding the molecular mechanisms that mediate the actions of glucocorticoids (GCs) in skin pathophysiology through functional analysis of the GC receptor (GR) and the mineralocorticoid receptor (MR), two highly related structural and functionally proteins, which act as ligand-dependent transcription factors. Our previous data show that GR plays a central role in skin development; in adulthood, both GR and MR act as anti-inflammatory mediators in skin diseases (Sevilla et al. 2013; Boix et al. 2016). However, we did not know if the receptors exerted cooperative or antagonistic functions in the epidermis. This doctoral thesis has focused on the generation and characterization of mice with specific inactivation in the epidermis of GR and MR (double knock-out or DKO mice). At birth, DKO show a skin phenotype with defective epidermal differentiation and a unique inflammatory state characterized by epithelial immune infiltrates and alterations in gene expression, similar to psoriatic lesions. This phenotype was much more severe than that of individual KO (GR epidermal KO or GREKO and MR epidermal KO or MREKO mice), but resolved spontaneously from postnatal day 3. In adulthood, DKO skin showed an increase in epidermal thickness, similar to that of individual KO. All KO mice showed greater susceptibility to acute inflammation compared to controls (CO), which was not effectively counteracted by topical treatment with GCs. Furthermore, DKO mice show a greater susceptibility to imiquimod-induced psoriasis relative to individual KO. The increased inflammatory response in DKO was consistent with a significant increase in AP-1 and NF-kappaB activity in DKO keratinocytes relative to CO or individual KO. Taken together, our data show that epidermal GR and MR act cooperatively to counteract skin inflammation, during development and adulthood, and that both are required for optimal transcriptional response and therapeutic activity of GCs. Prolonged treatments with pharmacological doses of GCs produce defects such as cutaneous atrophy, similar to that which occurs during chronological aging, which correlates with an increase in endogenous local levels of GCs. This work has addressed the phenotypic consequences of epidermal loss of MR during chronological aging and the mechanisms involved. The 13-month-old MREKO mice were resistant to epidermal atrophy but displayed reduced dermal thickness and collagen deposition, in part due to a decrease in SMAD2 3 activity relative to the skin of CO mice. In addition, the subcutaneous adipose tissue (dWAT) thickened 2.5 times in MREKO vs CO at 13 months, with hyperplasia and hypertrophy of adipocytes. These changes were triggered, at least in part, through alterations in GC-mediated signaling, and the activation of WNT/beta-catenin induced by epidermal paracrine signals that led to increased expression of Pparg. These results show a crucial role for epidermal MR in the regulation of the cross-talk between compartments during chronological skin aging. / Este trabajo ha sido realizado con el apoyo económico de los proyectos de investigación que se enumeran a continuación: SAF2014-59474-R, SAF2017-88046-R. Judit Bigas Corominas ha disfrutado de una beca predoctoral FPI (BES2015-072722) otorgada por el Ministerio de Economía y Competitividad, asociada al proyecto SAF2014-59474-R. Agradecemos el apoyo de COST ADMIRE BM-1301 y NuRCaMeIn (SAF2015-71878-REDT y SAF2017-90604-REDT). / Bigas Corominas, J. (2020). Contribuciones relativas de los receptores de glucocorticoides y mineralocorticoides en la biología cutánea [Tesis doctoral]. Universitat Politècnica de València. https://doi.org/10.4995/Thesis/10251/156214 / TESIS

京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第12957号 / 論医博第2099号 / 新制||医||1011(附属図書館) / 32356 / 京都大学大学院医学研究科医学専攻 / (主査)教授 生田 宏一, 教授 岩井 一宏, 教授 椛島 健治 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM